BioSpace19h
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Promising Biotech Stocks To Follow Today – February 05th
AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...
dermatologyadvisor2d
FDA Approves First New Non-Opioid Pain Pill in Decades
The US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
Best Biotech Stocks To Consider – February 03rd
AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...
Experts: Journavx a prescription to stem Long Island's addiction crisis
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
Newly approved painkiller Journavx is 'potentially groundbreaking'
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
FDA approves Journavx, the first new painkiller in over two decades
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...